SCROLL NEWS / DISCOVERY
Search headlines
Find the stories shaping the conversation.
Results for " Merck " 43 found 🔀 AI-powered Shuffle
Merck business unit opens R&D facility in Sheboygan Falls
EMD Electronics, the North America electronics business unit of Germany-based global health care and biopharmaceutical company Merck KGaA, today announced
Merck's holistic HIV health hive buzzes with the help of actress Debbie Allen
Merck’s newly unveiled HIV education program “Your Hive of Whole Health” is buzzing with the help of a queen bee in famed actor and HIV advocate Debbie Allen. | Merck's "Your Hive of Whole Health" brings together a hoard of educational resources and tips to promote holistic health for those living with HIV.
Merck Life Science Expands Bengaluru Manufacturing with €13 Million Investment
Merck Life Science is expanding its manufacturing capabilities in Bengaluru with an investment of approximately €13 million, strengthening the company’s ability to supply critical materials to customers across India and the wider Asia-Pacific region. The expansion at Merck Life Science’s Jigani site in Bengaluru will introduce biological buffer manufacturing alongside the facility’s established chemistry capabilities. The investment is designed to enable faster and more reliable access to critical materials used by customers across research, diagnostics, biotechnology and biopharmaceutical manufacturing. The development further advances Merck Life Science’s “in-region, for-region” approach, under which the company is expanding manufacturing capabilities closer to the markets and customers it serves. By adding biological buffer production in India, the Jigani expansion will broaden the site’s manufacturing capabilities while strengthening Merck Life Science’s regional supply infrastructure for the rapidly developing life sciences sector across India and Asia-Pacific. The company said the expansion reflects both the contribution of its teams and its collaboration with government and industry stakeholders. Merck Life Science acknowledged the support of India’s Department for Promotion of Industry and Internal Trade (DPIIT), the German Embassy New Delhi, and Invest India in helping strengthen life science manufacturing capabilities in the region. The investment comes as India continues to expand its role across pharmaceutical, biotechnology, diagnostics and biomanufacturing value chains, increasing demand for dependable regional access to materials supporting research and manufacturing operations. The Bengaluru expansion reinforces Merck Life Science’s focus on building manufacturing capacity within Asia-Pacific and supporting customers through a more regionalised supply network.
US lawmakers question Health Secretary Kennedy on vaccine settlement disclosures
A group of U.S. senators said Health Secretary Robert F. Kennedy Jr.'s recent explanation for how he disposed of a financial stake in litigation involving Merck's Gardasil vaccine conflicts with earlier answers he gave in written testimony and federal ethics filings, a letter reviewed by Reuters shows.
Health Care Roundup: Market Talk
Find insight on Moderna, Novonesis, Merck KGaA and more in the latest Market Talks covering the health care sector.
Moderna, Merck unveil mRNA-based cancer vaccine that cuts spread
Moderna's mRNA vaccine Intismeran shows promise, reducing melanoma recurrence and spread in late-stage trials.
Merck KGaA raises profit guidance on momentum in Life Science, Electronics units
Germany's Merck KGaA lifted its earnings guidance range for 2026 on Thursday, citing a further gain in demand for its drug manufacturing supplies and semiconductor materials, while posting better-than-expected quarterly results.
Merck Lifts Guidance on Life Science, Electronics
Merck KGaA lifted its full-year earnings and sales outlook thanks to a stronger performance in its lab equipment and electronics businesses.
Sanofi suspends chronic lung disease phase 2 study, tied to ‘strategic business reasons’
Sanofi halted a phase 2 trial testing a monoclonal antibody, SAR445399, in non-cystic fibrosis bronchiectasis, Fierce Biotech has learned. The trial, which began only back in April, was a randomized, double-blind, placebo-controlled study to measure the reduction in mucus plug score following treatment with SAR445399 compared with placebo in adults aged 18 to 80 years with NCFB, a chronic lung disease. The trial was officially reported as halted on July 29, the day before Sanofi’s second-quarter earnings call. The decision to pause the trial was made “as part of a company-wide portfolio review for strategic business reasons,” and not due to safety concerns, a Sanofi spokesperson told Fierce. The move to pause the NCFB trial comes during a trying time for Sanofi following a year filled with a series of trial fails. In February, the French pharma ousted CEO Paul Hudson and appointed Merck KGaA leader Belén Garijo, M.D., Ph.D., to steer the ship. Since then, Garijo has been doing a deep dive on correcting the company’s strewn R&D and clinical strategies. On July 24, Sanofi scrapped amlitelimab for atopic dermatitis, despite its lore as being a potential $5 billion blockbuster. During its second-quarter report, the company abandoned two more assets, balinatunfib and itepekimab, following failed trial results in psoriasis and chronic obstructive pulmonary disease, respectively. SAR445399, only first revealed by Sanofi in 2023, is an anti-interleukin-1 receptor 3 monoclonal antibody developed to block the interleukin 1, 33, and 36 cytokine pathways. These pathways can be important in chronic immune-related dermatologic diseases, such as atopic dermatitis and hidradenitis suppurativa, as well as respiratory conditions, such as NCFB. Related Sanofi’s new CEO ‘looking deeply’ at late-stage pipeline as clinical clearout continues NCFB affects roughly half a million people in the U.S., with a global incidence of greater than one million cases. In August 2025, Insmed received FDA approval for Brinsupri, a DPP1 inhibitor targeting neutrophil activation, for treatment of NCFB in adults and kids ages 12 and older. The British biotech Infex Therapeutics showed promising NCFB phase 2a data using their monoclonal antibody, INFEX702, which acts by disabling Pseudomonas aeruginosa, a bacteria known to be a major pathogen of NCFB. Sanofi is currently running a separate phase 2 study testing SAR445399 as a potential treatment for the inflammatory skin condition hidradenitis suppurativa.
Merck, Wellcome partner with global health group to make Ebola vaccine for clinical trials
Hilleman Laboratories, a Singapore-based joint venture between Merck and the global charity Wellcome, is gearing up to manufacture doses of a promising experimental vaccine against the rare Bundibugyo strain of Ebola responsible for a fast-spreading outbreak in the Democratic Republic of Congo.
Merck, Wellcome partner with global health group to make Ebola vaccine for clinical trials
CHICAGO, July 30 (Reuters) - Hilleman Laboratories, a Singapore-based joint venture between Merck and the global charity Wellcome, is gearing up to manufacture doses of a promising experimental vaccin...
US lawmakers press Health Secretary Robert F. Kennedy Jr. on vaccine settlement
The letter notes that Merck earlier this year agreed to pay $50 million to settle litigation over Gardasil.
US lawmakers press Health Secretary Robert F. Kennedy Jr. on vaccine settlement
A group of U.S. senators has asked Health Secretary Robert F. Kennedy Jr. to disclose whether his family stands to profit from a recent legal settlement involving Merck's Gardasil vaccine, according to a letter reviewed by Reuters.
FDA approves first cholesterol pill of its kind
Enlicitide, the new oral PCSK9 inhibitor from Merck, will be sold under the brand name Lipfendra. It is approved to reduce LDL-C in patients with hypercholesterolemia, including HeFH.
Merck’s cholesterol pill gets US FDA approval
Merck said on Thursday the U.S. FDA has approved its cholesterol pill, the first of its kind to receive the health regulator’s nod, bolstering the drugmaker’s efforts to diversify beyond its blockbuster cancer treatment Keytruda.
Cosmos Health Accelerates Prescription Medicine Strategy with Libytec Partnership to Commercialize DIABIT-IS X in Greece
Cosmos Health will supply DIABIT-IS X (sitagliptin), while Libytec handles distribution and promotion in GreeceFive-year agreement expected to contribute to revenue and cash-flow visibilityAs a prescription medicine, DIABIT-IS X is expected to be accessible to patients through Greece's national health insurance system, broadening its potential reachDIABIT-IS X is a generic alternative to Merck's Januvia®, which with Janumet® generated approximately $4.5 billion in combined global sales in 2022Po
Life Science Reagent Market Forecast Points Higher Toward 2035, Driven by Biopharma Scale-Up and Cell Therapy Expansion
World life science reagent market forecast 2026-2035: CAGR 6-8%, index 2035=185. Bioprocessing, cell therapy, and QC drive growth. Key players: Thermo Fisher, Merck, Danaher.
Merck KGaA to Acquire Bio-Techne for $11.3B, Expanding Life Science Tools Presence
Merck KGaA, Darmstadt, Germany, has agreed to acquire Bio-Techne for approximately $11.3 billion, the companies said today, in a deal designed to position the buyer as more of a leader across the life science value chain by expanding its presence in high-growth, next-generation life-sci markets with Bio-Techne’s tools, analytical technologies, and consumables.
Merck KGaA bolsters life sciences business with $11.3B Bio-Techne buy
The deal comes a matter of weeks after Kai Beckmann was promoted to CEO at Merck and signalled his intent to broaden the company's scope for M&A.
Merck KGaA to buy Bio-Techne for $11.3bn in life science footprint expansion
The deal is Merck’s largest since 2015, when it spent $17bn on acquiring Sigma-Aldrich, also a life sciences specialist.
Merck Expands Life Science Leadership with Planned $11.3 Billion Bio-Techne Acquisition
Merck Expands Life Science Leadership with Planned $11.3 Billion Bio-Techne Acquisition
Germany's Merck to buy Bio-Techne for $11.3 billion
Merck KGaA has agreed to acquire biotech firm Bio-Techne for $11.3 billion, the German science and healthcare firm said in a statement on Thursday.
Germany's Merck to buy Bio-Techne for $73 per share
Merck KGaA has agreed to acquire biotech firm Bio-Techne Corp for $73 per share in cash, the German science and healthcare firm said in a statement on Thursday.
Germany’s Merck to Buy Bio-Techne for $11 Billion
Merck KGaA offered $73 a share in cash to buy Bio-Techne, representing a 24% premium to the U.S. lab-tools supplier’s closing price Wednesday.
Rejuvenate Bio and Merck Animal Health Join Forces on Novel Animal Health Gene Therapy Programme
Rejuvenate Bio and Merck Animal Health Join Forces on Novel Animal Health Gene Therapy Programme
Local business purchases Loudoun Stairs in Purcellville
Purcellville-based Loudoun Stairs, a business founded by Brent Mercke nearly 40 years ago, was recently sold to local businessmen Scott Carpenter, Charles Beach, Paul Ferrari and Benjamin Carpenter.
Ebola, chemical plants and health, hantavirus, common colds, heat and more
As they say, bugs have ears. Public health has had a relentless May. Chemical plant (near) explosions, Ebola, hantavirus, and that's before you even get to the usual suspects: common colds, heat, and ticks. Here’s an attempt to keep you up to speed and, more importantly, what it means for you and your community. But first, an announcement: World Cup The World Cup starts in 15 days (not like anyone is counting down), and we are hanging TVs in the Health Security Operations Center. It’s going to be a gorgeous, chaotic celebration of basically every culture on earth. And it’s going to take a team effort—from communities to individuals, from public health to health care—to keep people healthy. That’s where you come in. If you’re going to the games or live within 30 miles of a stadium, we would love to hear from you. Sign up for a weekly survey here. Thanks to the more than 1,280 people who have already signed up…you will be hearing from us soon!! Global disease “weather report” Hantavirus: Two more cases The global count of cruise ship passengers with hantavirus has now increased to 13 cases (11 confirmed), with three deaths. The two new cases are overseas and among people who were already quarantining: A crew member in the Netherlands. A Spanish national passenger who was quarantining at home tested positive through daily monitoring. They are now in a biocontainment unit. In the U.S., everyone remains negative. There may be more cases, given that the incubation period of hantavirus (the time from exposure to infection) is 45 days. But this week, we will reach a major milestone: the median incubation window is 18 days, and that will pass on May 29. What this means for you: Your risk from this cruise ship outbreak remains essentially nil at this point. Ebola rages on in Central Africa Big thanks to Dr. Craig Spencer, a humanitarian physician who has treated and survived Ebola, for jumping in to provide the YLE community with an update. Craig, take it from here… The combined confirmed and suspected Ebola cases in DRC are now more than 1,000. All signs are pointing to a very long and catastrophic outbreak in Central Africa: This is a vast undercount. We know this because the test positivity rate is hovering around 50%, only 20% of contacts are being traced (and in some areas, no contacts at all), and more cases keep popping up with no known connection. This all points to widespread and undetected community transmission. This is in only a week of detection. Compared to previous outbreaks, the growth is very fast, as the huge West Africa outbreak in 2016 was first detected at 49 cases and rose to 208 cases a month later. It took four months for that outbreak to reach the size of the current one in the DR Congo. The cases are spread out across 16 health zones. There are now multiple epicenters, making containment very difficult. Next door in Uganda, the case count is seven. While this number is low compared to DRC, a concerning development is that two health care workers recently tested positive with uncertain exposure histories. If they weren’t treating known Ebola cases, this means it’s spreading undetected in Uganda as well. On the ground, backlash, including the burning of health centers, has emerged, a pattern seen in nearly every outbreak and rooted in deep community distrust. It often stems from outside actors working in communities without fully understanding or addressing local priorities. Affected populations may recognize the severity of Ebola while still holding other concerns as more pressing, such as where their loved ones are buried. Community trust is essential to an effective response, but difficult to build during an active emergency. It is best established long before a crisis begins. U.S. priorities are made clear, and may backfire. The U.S. Administration has shown that its first priority is keeping Ebola out, with helping end the outbreak in the DRC a secondary concern. That's meant travel restrictions broader than anything we've imposed before — covering travelers from across the region, and reportedly some green card holders and permanent residents as well. For example, just these past two days, news broke that high-risk American travelers will be subject to a mandatory quarantine in Kenya before they are allowed to return. If an American is infected, the U.S. government plans to send them to a hospital it is standing up from scratch in Kenya. (Currently, Americans who were in the area are allowed to return but are diverted to three airports—Houston, Atlanta, and DC—for further screening.) Past administrations have used travel notices and stepped-up screening; this goes much further. At first blush, these strict precautions may sound prudent. But this approach could backfire in three ways: Restrictions this blunt give people every reason to hide where they’ve been and whom they’ve been near — making the people we most need to find harder to track, not easier. They also breed a false sense that this is someone else’s problem. But diseases are humbling. They find the small cracks in even the most impenetrable-seeming defenses. Lives lost. There is no treatment for this Ebola strain, which means survival depends heavily on the quality of the health system. We have that system in the States, but we are choosing not to use it for infected Americans. This is unbelievable and infuriating. (See a deeper dive from me here.) The only real way to lower the risk to Americans — and everyone else — is to end the outbreak in the DRC and across the region. What this means for you: If you have travel plans to this region, it’s time to cancel them. This is a high-risk situation in Central Africa, and CDC released a Level 4 Travel Advisory. There is also great uncertainty if and when the Administration will let you back in. To the general public in the U.S., your risk remains very, very low right now. U.S. disease “weather report” Ticks: past peak season? Good news, especially for people in the Northeast and Midwest: tick numbers continue to decline. Though we are at the peak of the season, this unusually early year is trending favorably. Heat-related illnesses in the North Heat risk is certainly not blanketing the entire country yet, but this week it will be moderate in the Midwest and the Southeast. What this means for you: Be sure to check the CDC HeatRisk tool. A red day isn’t the best day for that soccer game for a kid with asthma, and a stretch of orange days is a great time to check on your elderly neighbor. Common colds surging As far as respiratory viruses go, the only thing really going around right now is the common cold. It is higher this year than last year, but should peak very soon before returning this fall. Spotlight: Chemical plants Over the weekend, YLE California covered the serious situation that unfolded around a chemical plant in Orange County, California. Thankfully, the worst-case scenario (a chemical explosion) was mitigated, but only through luck. The health implications in a densely populated area could have been catastrophic. As the situation was winding down, another chemical explosion struck Washington State. This one was fatal. Health officials say the risk to surrounding residents from chemicals in the air and ground remains low, though the community deserves far greater clarity. Clean air and clean water consistently rank as Americans’ top public health concerns — yet when chemical disasters strike, communities are too often met with reassurances rather than transparency and accountability. Residents near the 2023 East Palestine, Ohio train derailment, for example, are still waiting to understand the long-term impact on their health, with few clear answers. What this means for you: Many are wondering if facilities processing potentially dangerous materials are in their neighborhoods. This interactive map allows you to enter your ZIP code and see all facilities monitored by the EPA, including any violations. Good news Ebola vaccines and treatment for the Bundibugyo species are in development. Two vaccine platforms are being explored, at least one of which may be deployable in as little as 2 months. One vaccine is being developed by Oxford, and the other uses the same biotechnology as the FDA-approved Zaire species of Ebola. (It may provide cross-protection, but it’s unclear at this point.) On the treatment side, two promising monoclonal antibody cocktails are likely to be deployed, though doses are limited and logistical hurdles remain significant challenges. Anni over at The Biotech Tea had a great explainer about the Ebola vaccine gap, if you want to read more. [ The Biotech Tea The Ebola vaccine gap, reading vessel damage, & the Makary exit 🗝️ Paid subscribers get the Biotech Term of the Week at $30/year (~$2.50/month). I try to keep it intentionally accessible, but if cost is ever a barrier, send me a message. A few people asked about expensing your subscription, so I put together a short email template… Read more 6 days ago · 10 likes · Annicka Evans, PhD ](https://www.thebiotechtea.com/p/the-ebola-vaccine-gap-reading-vessel?utm_source=substack&utm_campaign=post_embed&utm_medium=web) Polycystic ovary syndrome (PCOS) has been officially renamed polyendocrine metabolic ovarian syndrome (PMOS), following more than a decade of debate and input from roughly 22,000 clinicians, researchers, and patients worldwide. This is good because the old name was medically misleading, leading to patients without visible cysts being dismissed or overlooked entirely. The WHO estimates that 70% of people with the condition remain undiagnosed. A more accurate name should improve recognition, reduce stigma, and ultimately help the millions of people living with this condition get diagnosed and treated sooner. Poll Loading... Bottom line Public health situations are everywhere right now. Staying healthy takes public health professionals and systems working tirelessly behind the scenes and each of us showing up for our neighbors and communities. Love, YLE Big thanks to Ed Nirenberg for staying on top of the Ebola vaccines, Hannah Totte for all the figures, Dr. Craig Spencer for the Ebola insight, and Dr. Matt Willis for covering the chemical situation in CA. Your Local Epidemiologist (YLE) comprises a team of experts, ranging from physicians to immunologists to epidemiologists to nutritionists, working together with one goal: to “Translate” ever-evolving public health science so that people are well-equipped to make evidence-based decisions. YLE suite of newsletters reaches over 475,000 people across more than 132 countries. This newsletter is free to everyone, thanks to the generous support of fellow YLE community members. To support the effort, subscribe or upgrade below: Subscribe
New drug approach offers hope for patients with recurrent aggressive cancers
Merck announces that sac-TMT, a new cancer drug, demonstrated strong results in phase 3 trials for advanced or recurrent endometrial cancer patients.
Health Care Roundup: Market Talk
Find insight on Merck KGaA, IHH Healthcare and more in the latest Market Talks covering the health care sector.
News | New Jersey tech university moves some labs to NEST science hub
School is bringing academic research to former Merck campus
At AACR, a provocative use of CAR-T, Merck’s new thing and cancer’s geography problem
At AACR, a bold use of CAR-T raises hopes and provocative questions about its use in smoldering multiple myeloma.
Merck KGaA acquires JSR chromatography business
Merck KGaA has completed its previously announced acquisition of the chromatography business of JSR Life Sciences.
Shawnee proposes TIF district to help businesses near Midland Drive, I-435 impacted by construction
City Manager Paul Kramer said a TIF would help with investments in development in the district using revenue generated by it, without creating additional sales taxes on businesses.
Health Care Roundup: Market Talk
Find insight on Merck KGaA, Bayer and more in the latest Market Talks covering the health care sector.
Girding against Keytruda cliff, Merck splits oncology into standalone business unit
The patent cliff for Keytruda is fast approaching in the U.S. Now, as Merck & Co. | The patent cliff for Keytruda is fast approaching in the U.S. Now, as Merck & Co. increasingly looks to life after its oncology megablockbuster, the company is honing its focus on new and upcoming medicines by splitting its core pharmaceutical business in two.
Merck to create separate cancer business to offset Keytruda patent loss
Merck said on Monday it will split its human-health business into two divisions, separating its cancer franchise from its non-oncology medicines.
Merck Evolves Human Health Operating Structure to Support Portfolio Execution
Merck Evolves Human Health Operating Structure to Support Portfolio Execution
Merck Evolves Human Health Operating Structure to Support Portfolio Execution
RAHWAY, N.J., February 23, 2026--Merck Evolves Human Health Operating Structure to Support Portfolio Execution
Merck to create separate cancer business to offset Keytruda patent loss, WSJ reports
Drugmaker Merck is separating its human-health business into two divisions to offset pressures related to the patent loss of its top-selling drug Keytruda, the Wall Street Journal reported on Monday.
Exclusive | Merck Creates Separate Cancer Business as Sales Pressure Looms
The drugmaker is splitting its pharmaceuticals unit to bolster product launches before a crucial patent loss.
Merck partners with global health coalition to develop affordable Ebola vaccine
Merck and the Coalition for Epidemic Preparedness Innovations said on Wednesday they have partnered on a $30 million program to develop an updated version of the drugmaker's Ebola vaccine aimed at improving affordability and access for low- and middle-income countries.
Merck CEO on US Business, Life Sciences Innovation
Merck KGaA Chief Executive Officer Belen Garijo says the company will continue to collaborate with the US and deliver life sciences innovation to patients. She spoke to Bloomberg's Francine Lacqua on the sidelines of the 2026 World Economic Forum in Davos, Switzerland. (Source: Bloomberg)